BCDA BioCardia: רווח נקי למניה (EPS TTM)

BioCardia, Inc. (BCDA) management is focused on developing innovative cell therapy to combat heart failure. Net income per share TTM reflects current trends, with the value stabilizing at -0.76. Business success is based on the effectiveness of the CardiAMP system, however, a shallow economic moat and dependence on regulators create significant development risks.

As a manager, I evaluate capital allocation efficiency through earnings per share. This metric divides total annual net income by the number of securities, excluding the impact of issuances. By analyzing the current trailing twelve-month net income per share, an investor determines the real value of the business. For BioCardia, Inc. (BCDA), this indicator reflects the costs of developing cell therapy. Negative values confirm the stage of costly clinical trials.